Literature DB >> 1454059

Autoantibodies to nucleolin cross-react with histone H1 in systemic lupus erythematosus.

W N Jarjour1, S Minota, R A Roubey, T Mimura, J B Winfield.   

Abstract

IgM autoantibodies to nucleolin and histone H1 are strongly associated in the serum of patients with systemic lupus erythematosus. IgM eluted from immobilized nucleolin specifically stained histone H1 blotted to nitrocellulose; conversely, IgM eluates prepared from immobilized histone H1 stained nucleolin blots. We conclude that the linkage of anti-nucleolin and anti-histone H1 autoantibodies in SLE is due, at least in part, to immunologic cross-reactivity between these two autoantigens, which share certain similar structural features.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1454059     DOI： 10.1007/bf00419666

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN： 0301-4851            Impact factor:   2.316


  19 in total

1.  Identification of three major target molecules of IgM antilymphocyte autoantibodies in systemic lupus erythematosus.

Authors:  S Minota; J B Winfield
Journal:  J Immunol       Date:  1987-12-01       Impact factor: 5.422

2.  Characterization of the DNA-binding protein antigen Ku recognized by autoantibodies from patients with rheumatic disorders.

Authors:  T Mimori; J A Hardin; J A Steitz
Journal:  J Biol Chem       Date:  1986-02-15       Impact factor: 5.157

3.  Splicing of messenger RNA precursors.

Authors:  P A Sharp
Journal:  Science       Date:  1987-02-13       Impact factor: 47.728

4.  Autoimmune sera reactive with Sm antigen contain high levels of RNP-like antibodies.

Authors:  W H Reeves; D E Fisher; R G Lahita; H G Kunkel
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

5.  Reactivity of autoantibodies and DNA/anti-DNA complexes with a novel 110-kilodalton phosphoprotein in systemic lupus erythematosus and other diseases.

Authors:  S Minota; W N Jarjour; R A Roubey; T Mimura; J B Winfield
Journal:  J Immunol       Date:  1990-02-15       Impact factor: 5.422

6.  Autoantibodies to nucleolin in systemic lupus erythematosus and other diseases.

Authors:  S Minota; W N Jarjour; N Suzuki; Y Nojima; R A Roubey; T Mimura; A Yamada; T Hosoya; F Takaku; J B Winfield
Journal:  J Immunol       Date:  1991-04-01       Impact factor: 5.422

7.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

8.  Identification of Ki (Ku, p70/p80) autoantigens and analysis of anti-Ki autoantibody reactivity.

Authors:  A M Francoeur; C L Peebles; P T Gompper; E M Tan
Journal:  J Immunol       Date:  1986-03-01       Impact factor: 5.422

9.  Procainamide elicits a selective autoantibody immune response.

Authors:  R L Rubin; G Reimer; E M McNally; S R Nusinow; R P Searles; E M Tan
Journal:  Clin Exp Immunol       Date:  1986-01       Impact factor: 4.330

10.  Interaction between anti-DNA and anti-DNA-binding protein autoantibodies in cryoglobulins from sera of patients with systemic lupus erythematosus.

Authors:  W H Reeves; N Chiorazzi
Journal:  J Exp Med       Date:  1986-10-01       Impact factor: 14.307
View more
  3 in total

Review 1.  Review of the "X chromosome-nucleolus nexus" hypothesis of autoimmune diseases with an update explaining disruption of the nucleolus.

Authors:  Wesley H Brooks
Journal:  Immunol Res       Date:  2018-12       Impact factor: 2.829

2.  Anti-human protein S antibody induces tissue factor expression through a direct interaction with platelet phosphofructokinase.

Authors:  Changyi Chen; Dan Liao; Jing Wang; Zhengdong Liang; Qizhi Yao
Journal:  Thromb Res       Date:  2013-11-16       Impact factor: 3.944

3.  Targeting surface nucleolin with multivalent HB-19 and related Nucant pseudopeptides results in distinct inhibitory mechanisms depending on the malignant tumor cell type.

Authors:  Bernard Krust; Diala El Khoury; Isabelle Nondier; Calaiselvy Soundaramourty; Ara G Hovanessian
Journal:  BMC Cancer       Date:  2011-08-03       Impact factor: 4.430
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.